My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.
What I am trying to establish is why a shortage listing created a legal pathway at all, since a shortage is a supply fact rather than a permission.
Happy to be told the question itself is wrong.
Answering the narrow version, because the broad one does not have a single answer. Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists. For 503B the shortage clause was the only route to these molecules, so that route shut completely. A 503A pharmacy can still argue a doorway via "component of an approved drug" — but only for the substance in the form present in the approved product, which is exactly where the base-versus-salt argument lives, and it does nothing about the copy restriction, which came back into force on resolution.
I would rather be corrected than agreed with, if it comes to it.
Dr.GastroMayo said:Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.
Dr.GastroMayo has the substance of this right. The condition it depends on is worth stating. Worth adding the genuine exception, because it is real and narrow: a change made for an identified patient where the prescriber determines it produces a significant clinical difference for that patient. A grid of fixed doses offered to everybody is not that, whatever the intake form says.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View Resultswanda_boise said:My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.
Same position here, arrived at the long way round. The shortage clause is the answer to the second question and it is a subtraction rather than an addition. Both exemptions forbid compounding something that is essentially a copy of a commercially available approved product. A product FDA has listed as in shortage is not treated as commercially available, so listing removed the objection that otherwise blocked compounding. It never created a permission; it withdrew a prohibition, which is why it evaporated the moment the supply fact changed.
Clinical perspective, offered as context rather than as advice.
Price comparison for compounded supply across sources I've used:
| Source | Monthly Cost | Type | Purity Verified |
|---|---|---|---|
| Brand (Ozempic) | $920 | FDA-approved | N/A (pharma) |
| 503B Compounding | $150 | cGMP compounded | Yes (in-house) |
| 503A Compounding | $110 | Patient-specific | Varies |
| Research peptide | $60 | Not for human use | Often Janoshik |
I use the 503B option — best balance of quality, cost, and legality. The brand price is insane but insurance can help if you qualify.